LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. (2021)

First Author: O'Connor MN
Attributed to:  A Phase I/IIa Clinical Trial of a Humanised Monoclonal Antibody Against LRG1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.medj.2021.10.002

PubMed Identifier: 35590198

Publication URI: http://europepmc.org/abstract/MED/35590198

Type: Journal Article/Review

Volume: 2

Parent Publication: Med (New York, N.Y.)

Issue: 11

ISSN: 2666-6340